UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
(X) QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 31, 1996
OR
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 0-15609
AGOURON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
CALIFORNIA 33-0061928
(State or other jurisdiction of (I.R.S. employer
incorporation or organization) identification no.)
10350 NORTH TORREY PINES ROAD, LA JOLLA, CALIFORNIA
92037-1020 (Address and zip code of principal
executive offices)
(619) 622-3000
(Registrant's telephone number, including area code)
NONE
(Former name, former address and former fiscal year,
if changed since last report.)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days:
Yes __X__ No ____
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date: Approximately 13,563,000 shares
of the Company's Common Stock, no par value, were outstanding as of January 8,
1997.
1
Item 6. Exhibits and Reports on Form 8-K:
a. Exhibits:
10.74 Letter of Intent between F. Hoffmann-La
Roche Ltd of Basel, Switzerland, Japan
Tobacco Inc., and the Company dated January
17, 1997. (Confidential treatment has been
requested for portions of this agreement
pursuant to an application dated January 27,
1997, as separately filed with the
Securities and Exchange Commission.)
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
AGOURON PHARMACEUTICALS, INC.
Date: June 25, 1997 /s/ Steven S. Cowell
-----------------------------
Steven S. Cowell
Vice President, Finance and Chief Financial
Officer and Chief Accounting Officer
3